Markets

Merck Says Topline Data From Phase 2b/3 BRUNELLO Trial Of Remigromig (MK-3000, Formerly EYE103) For Diabetic Macular Edema Met Its Primary Endpoint

Sep 24, 2026 · 06:48 AM ET· updated 1h ago

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema (DME). BRUNELLO is the first of

Why It Matters

Merck's new eye medicine passed an important safety and effectiveness test. When a big drug test succeeds, it shows the company might have a winner coming soon.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

MRK148.35

+0.27 (+0.18%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.